Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01820364 |
| Title | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma |
| Acronym | LOGIC |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ESP | DEU | CHE | CAN | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Sarah Cannon Research Institute Onc Dept | Nashville | Tennessee | 37203 | United States | Details | |
| Novartis Investigative Site | East Melbourne | Victoria | 3002 | Australia | Details | |
| Novartis Investigative Site | Edmonton | Alberta | T6G 1Z2 | Canada | Details | |
| Novartis Investigative Site | Heidelberg | 69120 | Germany | Details | ||
| Novartis Investigative Site | Barcelona | Catalunya | 08035 | Spain | Details | |
| Novartis Investigative Site | Zuerich | 8091 | Switzerland | Details |